{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:40:15Z","timestamp":1789594815423,"version":"build-2803163510"},"reference-count":125,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Polymyalgia Rheumatica (PMR) is an inflammatory condition that primarily affects individuals aged 50 and older, especially in Western countries. Although glucocorticoids are the cornerstone of PMR treatment, these drugs are associated with side effects, making it advisable to use them for the shortest duration possible. However, tapering or discontinuation of glucocorticoids often leads to disease relapses. In this review, we focus on the traditional management of PMR, as well as the potential for therapies that may reduce glucocorticoid use. Special attention is given to the efficacy of biologic agents in PMR management. Methods: A literature review, primarily based on articles published in PubMed, was conducted. In addition to discussing various glucocorticoids and conventional disease-modifying drugs used for the management of isolated PMR, this review specifically focused on the information reported regarding new therapies, with particular emphasis on biologic agents. Results: Prednisone or prednisolone at a dose ranging between 12.5 and 25 mg\/day is the agreed-upon treatment for PMR. Due to the side effects associated with prolonged glucocorticoid use and the high frequency of relapses when glucocorticoids are tapered, glucocorticoid-sparing agents have emerged as tools in the management of PMR. Methotrexate has traditionally been the conventional disease-modifying antirheumatic drug (DMARD) unanimously recommended for use in PMR. Other conventional DMARDs, such as leflunomide, have shown promising results but require further study. The use of biologic agents has marked a significant step forward in the management of PMR. While anti-TNF agents failed to provide beneficial effects in isolated PMR, anti-IL-6 receptor agents, such as tocilizumab and sarilumab, have demonstrated efficacy in reducing relapse frequency, lowering the cumulative glucocorticoid burden, and achieving long-term remission of the disease. Other biologic agents, many of which have been used in giant cell arteritis, as well as Janus kinase (JAK) inhibitors, are currently under investigation. Conclusions: Glucocorticoids are the primary treatment for isolated PMR but are associated with comorbidities, especially in patients with pre-existing conditions or frequent relapses. Glucocorticoid-sparing agents, such as methotrexate and biologics, in particular tocilizumab and sarilumab, offer alternatives, improving symptoms and reducing glucocorticoid use. While biologic agents reduce long-term side effects and help achieve disease remission, their use must consider potential side effects and higher costs compared to traditional therapies.<\/jats:p>","DOI":"10.3390\/jcm13216492","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T12:09:18Z","timestamp":1730203758000},"page":"6492","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Traditional and Emerging Strategies for Managing Polymyalgia Rheumatica: Insights into New Treatments"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4933-957X","authenticated-orcid":false,"given":"Carlos","family":"Garc\u00eda-Porr\u00faa","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Hospital Lucus-Augusti, 27003 Lugo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Heras-Recuero","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, IIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Bl\u00e1zquez-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, IIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arantxa","family":"Torres-Rosell\u00f3","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, IIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7748-853X","authenticated-orcid":false,"given":"Santos","family":"Casta\u00f1eda","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Hospital Universitario de la Princesa, Instituto de Investigaci\u00f3n del Hospital de La Princesa, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7924-7406","authenticated-orcid":false,"given":"Miguel \u00c1ngel","family":"Gonz\u00e1lez-Gay","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, IIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz, 28040 Madrid, Spain"},{"name":"Medicine and Psychiatry Department, University of Cantabria, 39008 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0140-6736(17)31825-1","article-title":"Polymyalgia rheumatica","volume":"390","author":"Matteson","year":"2017","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/jama.2024.7330","article-title":"What Is Polymyalgia Rheumatica?","volume":"332","author":"Lall","year":"2024","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/art.24459","article-title":"Epidemiology of giant cell arteritis and polymyalgia rheumatica","volume":"61","author":"Martin","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/joim.13525","article-title":"An update on polymyalgia rheumatica","volume":"292","author":"Lundberg","year":"2022","journal-title":"J. Intern. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.semarthrit.2020.07.005","article-title":"Incidence and prevalence of giant cell arteritis and polymyalgia rheumatica: A systematic literature review","volume":"50","author":"Sharma","year":"2020","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/archinte.1997.00440240081012","article-title":"Polymyalgia rheumatica without significantly increased erythrocyte sedimentation rate. A more benign syndrome","volume":"157","author":"Blanco","year":"1997","journal-title":"Arch. Intern. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/annrheumdis-2011-200329","article-title":"2012 provisional classification criteria for polymyalgia rheumatica: A European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"71","author":"Dasgupta","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1002\/1529-0131(200008)43:8<1749::AID-ANR11>3.0.CO;2-K","article-title":"Association of giant cell arteritis and polymyalgia rheumatica with different tumor necrosis factor microsatellite polymorphisms","volume":"43","author":"Mattey","year":"2000","journal-title":"Arthritis Rheum."},{"key":"ref_9","first-page":"2140","article-title":"Giant cell arteritis and polymyalgia rheumatica can be differentiated by distinct patterns of HLA class II association","volume":"25","author":"Dababneh","year":"1998","journal-title":"J. Rheumatol."},{"key":"ref_10","first-page":"S18","article-title":"Interferon-gamma gene microsatellite polymorphisms in patients with biopsy-proven giant cell arteritis and isolated polymyalgia rheumatica","volume":"22","author":"Hajeer","year":"2004","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Zhao, S.S., Mackie, S.L., Larsson, S.C., Burgess, S., and Yuan, S. (2024). Modifiable risk factors and inflammation-related proteins in polymyalgia rheumatica: Genome-wide meta-analysis and Mendelian randomisation. Rheumatology, keae308.","DOI":"10.1101\/2024.04.21.24306135"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"102732","DOI":"10.1016\/j.autrev.2020.102732","article-title":"Giant cell arteritis or polymyalgia rheumatica after influenza vaccination: A study of 12 patients and a literature review","volume":"20","author":"Liozon","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"105150","DOI":"10.1016\/j.jbspin.2021.105150","article-title":"Can SARS-CoV-2 trigger relapse of polymyalgia rheumatica?","volume":"88","author":"Manzo","year":"2021","journal-title":"Joint Bone Spine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1056\/NEJMra011913","article-title":"Polymyalgia rheumatica and giant-cell arteritis","volume":"347","author":"Salvarani","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.cpet.2019.12.001","article-title":"Use of 18F-Fluorodeoxyglucose PET in the Diagnosis and Follow-up of Polymyalgia Rheumatica","volume":"15","author":"Betrains","year":"2020","journal-title":"PET Clin."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2967\/jnumed.122.265016","article-title":"Role of 18F-FDG PET\/CT in Large Vessel Vasculitis and Polymyalgia Rheumatica","volume":"64","author":"Slart","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_17","first-page":"2179","article-title":"The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain","volume":"27","author":"Salvarani","year":"2000","journal-title":"J. Rheumatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1080\/03009742.2023.2215044","article-title":"Differential diagnostics of polymyalgia rheumatica in a university hospital in Finland","volume":"52","author":"Paltta","year":"2023","journal-title":"Scand. J. Rheumatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1186\/s13256-022-03535-z","article-title":"Idiopathic remitting seronegative symmetrical synovitis with pitting edema syndrome mimicking symptoms of polymyalgia rheumatica: A case report","volume":"16","author":"Dumusc","year":"2022","journal-title":"J. Med. Case Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3399\/bjgp12X641636","article-title":"Diagnosis and management of polymyalgia rheumatica","volume":"62","author":"Helliwell","year":"2012","journal-title":"Br. J. Gen. Pract."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"103415","DOI":"10.1016\/j.autrev.2023.103415","article-title":"Subclinical giant cell arteritis in polymyalgia rheumatica: Concurrent conditions or a common spectrum of inflammatory diseases?","volume":"23","author":"Salvarani","year":"2024","journal-title":"Autoimmun. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Heras-Recuero, E., Bl\u00e1zquez-S\u00e1nchez, T., Landaeta-Kancev, L.C., Mart\u00ednez de Bourio-Allona, M., Torres-Rosell\u00f3, A., Rengifo-Garc\u00eda, F., Caraballo-Salazar, C., Largo, R., Casta\u00f1eda, S., and Gonz\u00e1lez-Gay, M.A. (2024). Positron Emission Tomography\/Computed Tomography in Polymyalgia Rheumatica: When and for What\u2014A Critical Review. Diagnostics, 14.","DOI":"10.20944\/preprints202406.1405.v1"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.semarthrit.2015.06.009","article-title":"Prevalence of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatica","volume":"45","author":"Estrada","year":"2015","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1080\/1744666X.2024.2356741","article-title":"Broadening the clinical spectrum of giant cell arteritis: From the classic cranial to the predominantly extracranial pattern of the disease","volume":"20","author":"Largo","year":"2024","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"101424","DOI":"10.1016\/j.berh.2019.06.006","article-title":"Early large vessel systemic vasculitis in adults","volume":"33","author":"Banzo","year":"2019","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"627","DOI":"10.2165\/00002512-200623080-00002","article-title":"Giant cell arteritis and polymyalgia rheumatica: Pathophysiology and management","volume":"23","author":"Martin","year":"2006","journal-title":"Drugs Aging."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0140-6736(12)60680-1","article-title":"Polymyalgia rheumatica","volume":"381","author":"Kermani","year":"2013","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1001\/archinternmed.2009.352","article-title":"Treatment of Polymyalgia Rheumatica. A systematic review","volume":"169","author":"Cid","year":"2009","journal-title":"Arch. Intern. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/ard.2010.133850","article-title":"Definition of remission and relapse in polymyalgia rheumatica: Data from a literature search compared with a Delphi-based expert consensus","volume":"70","author":"Dejaco","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/1744666X.2021.1890032","article-title":"Predicting the risk of relapse in polymyalgia rheumatica: Novel insights","volume":"17","author":"Blanco","year":"2021","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/art.20901","article-title":"Acute-phase reactants and the risk of relapse\/recurrence in polymyalgia rheumatica: A prospective followup study","volume":"53","author":"Salvarani","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/0049-0172(84)90012-X","article-title":"Long-term follow-up of polymyalgia rheumatica: Evidence for synovitis","volume":"13","author":"Healey","year":"1984","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1001\/jama.2016.5444","article-title":"Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review","volume":"315","author":"Buttgereit","year":"2016","journal-title":"JAMA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"672","DOI":"10.7326\/0003-4819-97-5-672","article-title":"Polymyalgia rheumatica: A 10-year epidemiologic and clinical study","volume":"97","author":"Chuang","year":"1982","journal-title":"Ann. Intern. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/sarh.2000.8366","article-title":"Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: A prospective follow-up study","volume":"30","author":"Cantini","year":"2000","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.0954-6820.1981.tb11604.x","article-title":"Prognosis of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. A follow-up study on ninety patients treated with corticosteroids","volume":"209","author":"Bengtsson","year":"1981","journal-title":"Acta Med. Scand."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.0954-6820.1979.tb06077.x","article-title":"Treatment and prognosis in polymyalgia rheumatica and temporal arteritis. A ten-year survey of 53 patients","volume":"205","year":"1979","journal-title":"Acta Med. Scand."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"keae428","DOI":"10.1093\/rheumatology\/keae428","article-title":"Definitions of and Instruments for Disease Activity, Remission, and Relapse in Polymyalgia Rheumatica: A Systematic Literature Review","volume":"12","author":"Bolhuis","year":"2024","journal-title":"Rheumatology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/art.22771","article-title":"The polymyalgia rheumatica activity score in daily use: Proposal for a definition of remission","volume":"57","author":"Leeb","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/art.23338","article-title":"Inflammatory Joint Disease Working Group of the French Society for Rheumatology. Performance of the polymyalgia rheumatica activity score for diagnosing disease flares","volume":"59","author":"Binard","year":"2008","journal-title":"Arthritis Rheum."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(23)01310-7","article-title":"Polymyalgia rheumatica","volume":"402","author":"Dejaco","year":"2023","journal-title":"Lancet"},{"key":"ref_42","first-page":"65","article-title":"Relapse in a population based cohort of patients with polymyalgia rheumatica","volume":"32","author":"Kremers","year":"2005","journal-title":"J. Rheumatol."},{"key":"ref_43","first-page":"1326","article-title":"The spectrum of polymyalgia rheumatica in northwestern Spain: Incidence and analysis of variables associated with relapse in a 10 year study","volume":"26","author":"Dababneh","year":"1999","journal-title":"J. Rheumatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s40266-019-00705-5","article-title":"Pathogenesis, Diagnosis and Management of Polymyalgia Rheumatica","volume":"36","author":"Camellino","year":"2019","journal-title":"Drugs Aging"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/ard.42.4.374","article-title":"Polymyalgia rheumatica and corticosteroids: How much for how long?","volume":"42","author":"Behn","year":"1983","journal-title":"Ann. Rheum. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/ard.52.12.847","article-title":"The clinical and laboratory course of polymyalgia rheumatica\/giant cell arteritis after the first two months of treatment","volume":"52","author":"Kyle","year":"1993","journal-title":"Ann. Rheum. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s00296-012-2580-4","article-title":"Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR)","volume":"33","author":"Lee","year":"2013","journal-title":"Rheumatol. Int."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1053\/sarh.2002.32552","article-title":"Influence of human leukocyte antigen-DRB1 on the susceptibility and severity of rheumatoid arthritis","volume":"31","author":"Hajeer","year":"2002","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_49","first-page":"703","article-title":"Relationship between interleukin 6 promoter polymorphism at position -174, IL-6 serum levels, and the risk of relapse\/recurrence in polymyalgia rheumatica","volume":"33","author":"Boiardi","year":"2006","journal-title":"J. Rheumatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/rheumatology\/kep303a","article-title":"BSR and BHPR guidelines for the management of polymyalgia rheumatica","volume":"49","author":"Dasgupta","year":"2010","journal-title":"Rheumatology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.39333","article-title":"2015 recommendations for the management of polymyalgia rheumatica: A European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"67","author":"Dejaco","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/rheumatology\/kead471","article-title":"Evidence on treat to target strategies in polymyalgia rheumatica and giant cell arteritis: A systematic literature review","volume":"63","author":"Hysa","year":"2024","journal-title":"Rheumatology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"f6937","DOI":"10.1136\/bmj.f6937","article-title":"Polymyalgia rheumatica","volume":"347","author":"Mackie","year":"2013","journal-title":"BMJ"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.rdc.2015.08.009","article-title":"Glucocorticoids for management of polymyalgia rheumatica and giant cell arteritis","volume":"42","author":"Matteson","year":"2016","journal-title":"Rheum. Dis. Clin. North. Am."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1517\/14656561003724739","article-title":"Medical management of polymyalgia rheumatica","volume":"11","author":"Agudo","year":"2010","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","article-title":"2015 Recommendations for the management of polymyalgia rheumatica: A European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"74","author":"Dejaco","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bcp.2019.03.027","article-title":"Treatment of polymyalgia rheumatica","volume":"165","author":"Vicente","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11926-014-0480-1","article-title":"Giant cell arteritis and polymyalgia rheumatica: An update","volume":"17","author":"Pina","year":"2015","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1136\/annrheumdis-2015-207578","article-title":"Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: A systematic literature review informing the 2015 European League Against Rheumatism\/American College of Rheumatology recommendations for the management of polymyalgia rheumatica","volume":"74","author":"Dejaco","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_60","first-page":"1","article-title":"Glucocorticoid withdrawal in polymyalgia rheumatica: The theory versus the practice","volume":"35","author":"Yates","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3899\/jrheum.091283","article-title":"More night than day--circadian rhythms in polymyalgia rheumatica and ankylosing spondylitis","volume":"37","author":"Spies","year":"2010","journal-title":"J. Rheumatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/1756-185X.13149","article-title":"A 26-week feasibility study comparing the efficacy and safety of modified-release prednisone with immediate-release prednisolone in newly diagnosed cases of giant cell arteritis","volume":"21","author":"Raine","year":"2018","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e000426","DOI":"10.1136\/rmdopen-2016-000426","article-title":"Modified-release prednisone for polymyalgia rheumatica: A multicentre, randomised, active-controlled, double-blind, parallel-group study","volume":"3","author":"Cutolo","year":"2017","journal-title":"RMD Open"},{"key":"ref_64","first-page":"1470","article-title":"Corticosteroid injections in polymyalgia rheumatica: A double-blind, prospective, randomized, placebo controlled study","volume":"27","author":"Salvarani","year":"2000","journal-title":"J. Rheumatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/rheumatology\/37.2.189","article-title":"An initially double-blind controlled 96-week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica","volume":"37","author":"Dasgupta","year":"1998","journal-title":"Br. J. Rheumatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"493","DOI":"10.7326\/0003-4819-141-7-200410050-00005","article-title":"Prednisone plus methotrexate for polymyalgia rheumatica: A randomized, double-blind, placebo-controlled trial","volume":"141","author":"Caporali","year":"2004","journal-title":"Ann. Intern. Med."},{"key":"ref_67","first-page":"624","article-title":"Methotrexate in polymyalgia rheumatica: Preliminary results of an open, randomized study","volume":"23","author":"Ferraccioli","year":"1996","journal-title":"J. Rheumatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1136\/ard.55.4.218","article-title":"Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?","volume":"55","author":"Dinant","year":"1996","journal-title":"Ann. Rheum. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Diamantopoulos, A.P., Hetland, H., and Myklebust, G. (2013). Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: A case series. BioMed Res. Int., 2013.","DOI":"10.1155\/2013\/120638"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/j.1742-1241.2012.02981.x","article-title":"Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: A case series","volume":"66","author":"Adizie","year":"2012","journal-title":"Int. J. Clin. Pract."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"rkae033","DOI":"10.1093\/rap\/rkae033","article-title":"Effectiveness of methotrexate and leflunomide as corticoid-sparing drugs in patients with polymyalgia rheumatica","volume":"8","author":"Vinicki","year":"2024","journal-title":"Rheumatol. Adv. Pract."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"rkae047","DOI":"10.1093\/rap\/rkae047","article-title":"Leflunomide as a therapeutic alternative to methotrexate as a glucocorticoid-sparing agent in polymyalgia rheumatica","volume":"8","author":"Largo","year":"2024","journal-title":"Rheumatol. Adv. Pract."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/s13063-022-06263-3","article-title":"PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Early disease phase (PMR MODE): Study protocol for a multicenter double-blind placebo controlled trial","volume":"23","author":"Marsman","year":"2022","journal-title":"Trials"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"103590","DOI":"10.1016\/j.autrev.2024.103590","article-title":"The pipeline of immunomodulatory therapies in polymyalgia rheumatica and giant cell arteritis: A systematic review of clinical trials","volume":"23","author":"Kawka","year":"2024","journal-title":"Autoimmun. Rev."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/ard.45.2.136","article-title":"Azathioprine in giant cell arteritis\/polymyalgia rheumatica: A double-blind study","volume":"45","author":"Hazleman","year":"1986","journal-title":"Ann. Rheum. Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2147\/OARRR.S101911","article-title":"Polymyalgia rheumatica: Observations of disease evolution without corticosteroid treatment","volume":"8","author":"Brawer","year":"2016","journal-title":"Open Access Rheumatol."},{"key":"ref_77","first-page":"760","article-title":"Treatment of refractory polymyalgia rheumatica with infliximab: A pilot study","volume":"30","author":"Salvarani","year":"2003","journal-title":"J. Rheumatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"631","DOI":"10.7326\/0003-4819-146-9-200705010-00005","article-title":"Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: A randomized trial","volume":"146","author":"Salvarani","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1080\/14712598.2023.2287097","article-title":"Biological therapy in polymyalgia rheumatica","volume":"23","author":"Wendling","year":"2023","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"R176","DOI":"10.1186\/ar3140","article-title":"Effect of etanercept in polymyalgia rheumatica: A randomized controlled trial","volume":"12","author":"Kreiner","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.semarthrit.2021.03.006","article-title":"Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial","volume":"51","author":"Spiera","year":"2021","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1136\/annrheumdis-2021-221126","article-title":"Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): A phase 2\/3 randomised controlled trial","volume":"81","author":"Bonelli","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1001\/jama.2022.15459","article-title":"Effect of Tocilizumab on Disease Activity in Patients with Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial","volume":"328","author":"Dernis","year":"2022","journal-title":"JAMA"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1056\/NEJMoa2303452","article-title":"Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper","volume":"389","author":"Spiera","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nrrheum.2017.142","article-title":"Giant cell arteritis and polymyalgia rheumatica: Current challenges and opportunities","volume":"13","author":"Dejaco","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/rheumatology\/29.6.456","article-title":"Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis","volume":"29","author":"Dasgupta","year":"1990","journal-title":"Br. J. Rheumatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/BOR.0b013e32835b133a","article-title":"New treatment strategies in large-vessel vasculitis","volume":"25","author":"Unizony","year":"2013","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2146\/ajhp070449","article-title":"Tocilizumab: The first interleukin-6-receptor inhibitor","volume":"65","author":"Sebba","year":"2008","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.semarthrit.2003.09.007","article-title":"Giant cell arteritis and polymyalgia rheumatica: Two different but often overlapping conditions","volume":"33","year":"2004","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.semarthrit.2014.12.005","article-title":"Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients","volume":"44","author":"Loricera","year":"2015","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.3899\/jrheum.151252","article-title":"Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients","volume":"43","author":"Redeker","year":"2016","journal-title":"J. Rheumatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","article-title":"Tocilizumab for induction and maintenance of remission in giant cell arteritis: A phase 2, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Villiger","year":"2016","journal-title":"Lancet"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of Tocilizumab in Giant cell Arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1002\/acr.21750","article-title":"Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica","volume":"64","author":"Unizony","year":"2012","journal-title":"Arthritis Care Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/RHU.0b013e3182a6aa0e","article-title":"Effective control of polymyalgia rheumatica with tocilizumab","volume":"19","author":"Hegazi","year":"2013","journal-title":"J. Clin. Rheumatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3899\/jrheum.091185","article-title":"Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica","volume":"37","author":"Hagihara","year":"2010","journal-title":"J. Rheumatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.semarthrit.2013.01.003","article-title":"Tocilizumab for polymyalgia rheumatica: Report of two cases and review of the literature","volume":"43","author":"Macchioni","year":"2013","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s10067-014-2650-y","article-title":"Glucocorticoid-resistant polymyalgia rheumatica: Pretreatment characteristics and tocilizumab therapy","volume":"35","author":"Mori","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00296-018-4086-1","article-title":"Dissecting the inflammatory response in polymyalgia rheumatica: The relative role of IL-6 and its inhibition","volume":"38","author":"Camellino","year":"2018","journal-title":"Rheumatol. Int."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3899\/jrheum.150599","article-title":"Rapid and Sustained Response to Tocilizumab in Patients with Polymyalgia Rheumatica Resistant or Intolerant to Glucocorticoids: A Multicenter Open-label Study","volume":"43","author":"Toussirot","year":"2016","journal-title":"J. Rheumatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1093\/rheumatology\/kead426","article-title":"Efficacy and management of tocilizumab in polymyalgia rheumatica: Results of a multicentre retrospective observational study","volume":"63","author":"Assaraf","year":"2024","journal-title":"Rheumatology"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1136\/annrheumdis-2015-208742","article-title":"Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: A prospective longitudinal study","volume":"75","author":"Berthelot","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1111\/1756-185X.13723","article-title":"Tocilizumab monotherapy for polymyalgia rheumatica: A prospective, single-center, open-label study","volume":"22","author":"Chino","year":"2019","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/art.39740","article-title":"Brief Report: A Prospective Open-Label Phase IIa Trial of Tocilizumab in the Treatment of Polymyalgia Rheumatica","volume":"68","author":"Lally","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1002\/art.34647","article-title":"Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis","volume":"64","author":"Samson","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_106","first-page":"S391","article-title":"A two-week single-blind, randomized 3-arm proof of concept study of the effects of secukinumab (anti-IL17 mAb), canakinumab (anti-IL-1 b mAb), or corticosteroids on initial disease activity scores in patients with PMR, followed by an open-label extension","volume":"66","author":"Matteson","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e758","DOI":"10.1016\/S2665-9913(21)00245-9","article-title":"Efficacy of rituximab in patients with polymyalgia rheumatica: A double-blind, randomised, placebo-controlled, proof-of-concept trial","volume":"3","author":"Marsman","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(23)00032-2","article-title":"1-year results of treatment with rituximab in polymyalgia rheumatica: An extension study of a randomised double-blind placebo-controlled trial","volume":"5","author":"Bolhuis","year":"2023","journal-title":"Lancet Rheumatol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/art.40037","article-title":"A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis","volume":"69","author":"Langford","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e728","DOI":"10.1016\/S2665-9913(23)00246-1","article-title":"Abatacept in early polymyalgia rheumatica (ALORS): A proof-of-concept, randomised, placebo-controlled, parallel-group trial","volume":"5","author":"Saraux","year":"2023","journal-title":"Lancet Rheumatol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: Current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"ii111","DOI":"10.1136\/annrheumdis-2012-202576","article-title":"Janus kinase inhibitors in autoimmune diseases","volume":"72","author":"Kontzias","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Ma, X., Yang, F., Wu, J., Xu, B., Jiang, M., Sun, Y., Sun, C., Yu, Y., Xu, D., and Xiao, L. (2023). Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): An open-label randomized controlled trial. PLoS Med., 20.","DOI":"10.1371\/journal.pmed.1004249"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard-2022-223429","article-title":"Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica","volume":"83","author":"Dejaco","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/13543784.2024.2366847","article-title":"Investigational agents for polymyalgia rheumatica treatment: Assessing the critical needs for future development","volume":"33","author":"Iorio","year":"2024","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.semarthrit.2018.05.007","article-title":"Predictors of positive 18F-FDG PET\/CT-scan for large vessel vasculitis in patients with persistent polymyalgia rheumatica","volume":"48","author":"Loricera","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Heras-Recuero, E., Landaeta-Kancev, L.C., Mart\u00ednez de Bourio-Allona, M., Torres-Rosello, A., Bl\u00e1zquez-S\u00e1nchez, T., Ferraz-Amaro, I., Casta\u00f1eda, S., Mart\u00ednez-L\u00f3pez, J.A., Mart\u00ednez-Dhier, L., and Largo, R. (2023). Positron Emission Computed Tomography Spectrum of Large Vessel Vasculitis in a Tertiary Center: Differences in 18F-fluorodeoxyglucose Uptake between Large Vessel Vasculitis with Predominant Cranial and Extracranial Giant Cell Arteritis Phenotypes. J. Clin. Med., 12.","DOI":"10.3390\/jcm12196164"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"rkae081","DOI":"10.1093\/rap\/rkae081","article-title":"The relationship between obesity and patient-reported outcome measures in people with polymyalgia rheumatica","volume":"8","author":"Scott","year":"2024","journal-title":"Rheumatol. Adv. Pract."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.pharmthera.2015.05.001","article-title":"Selective glucocorticoid receptor modulation: New directions with non-steroidal scaffolds","volume":"152","author":"Sundahl","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Van Moortel, L., Gevaert, K., and De Bosscher, K. (2020). Improved Glucocorticoid Receptor Ligands: Fantastic Beasts, but How to Find Them?. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.559673"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1021\/mp2000742","article-title":"Liposomal drug formulations in the treatment of rheumatoid arthritis","volume":"8","author":"Metselaar","year":"2011","journal-title":"Mol. Pharm."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Vani, K., Kriplani, P., Dhingra, A., Chopra, B., Singh Grewal, A., Deswal, G., Dass, R., and Guarve, K. (2024). Liposomes: An Emerging Strategy for the Effective Treatment of Rheumatoid Arthritis. Curr. Rheumatol. Rev.","DOI":"10.2174\/0115733971284274240215064826"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"103589","DOI":"10.1016\/j.autrev.2024.103589","article-title":"Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: A systematic literature review highlighting differences from the idiopathic forms","volume":"23","author":"Hysa","year":"2024","journal-title":"Autoimmun. Rev."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4081\/reumatismo.2018.1039","article-title":"Comorbidity in polymyalgia rheumatica","volume":"70","author":"Chatzigeorgiou","year":"2018","journal-title":"Reumatismo"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.semarthrit.2020.05.003","article-title":"Comorbidities in patients with polymyalgia rheumatica prior to and following diagnosis: A case control and cohort study","volume":"50","author":"Partington","year":"2020","journal-title":"Semin. Arthritis Rheum."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/21\/6492\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:23:26Z","timestamp":1760113406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/21\/6492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":125,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["jcm13216492"],"URL":"https:\/\/doi.org\/10.3390\/jcm13216492","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,29]]}}}